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Abstract
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma
(RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to
investigate the relative efficacy of allosteric versus catalytic mTOR inhibition, evaluate the crosstalk between the mTOR and
MEK/ERK pathways, as well as the therapeutic potential of dual mTOR and MEK inhibition in RCC. Pharmacologic (rapamycin
and BEZ235) and genetic manipulation of the mTOR pathway were evaluated by in vitro assays as monotherapy as well as in
combination with MEK inhibition (GSK1120212). Catalytic mTOR inhibition with BEZ235 decreased proliferation and
increased apoptosis better than allosteric mTOR inhibition with rapamycin. While mTOR inhibition upregulated MEK/ERK
signaling, concurrent inhibition of both pathways had enhanced therapeutic efficacy. Finally, primary RCC tumors could be
classified into subgroups [(I) MEK activated, (II) Dual MEK and mTOR activated, (III) Not activated, and (IV) mTOR activated]
based on their relative activation of the PI3K/mTOR and MEK pathways. Patients with mTOR only activated tumors had the
worst prognosis. In summary, dual targeting of the mTOR and MEK pathways in RCC can enhance therapeutic efficacy and
primary RCC can be subclassified based on their relative levels of mTOR and MEK activation with potential therapeutic
implications.
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Introduction
Recent statistics suggest that there are predicted to be roughly
65,000 new cases and 14,000 deaths in 2013 from renal cell
carcinoma (RCC) [1,2]. Clear cell renal cell carcinoma (ccRCC) is
the most common histologic subtype of RCC and the vast majority
of sporadic ccRCC have inactivation of the von Hippel-Lindau
tumor suppressor protein (pVHL). Patients with VHL disease have
inherited mutations of VHL and renal cyst and/or tumors develop
when these individuals undergo somatic inactivation or loss of the
remaining wild-type VHL allele [3,4]. pVHL’s most well
understood function is to negatively regulate the hypoxia-inducible
factor alpha (HIFa) family of transcription factors (HIF1a, HIF2a,
HIF3a) in an oxygen dependent manner via its E3 ubiquitin ligase
activity [5,6]. Importantly, pVHL’s tumor suppressor function is
dependent upon the downregulation of HIFa subunits and in
particular HIF2a [7–9].
Stabilization of HIFa, either as a consequence of hypoxia or
pVHL inactivation leads to transcriptional activation of numerous
genes associated with adaptation to a hypoxic environment as well
as an unfavorable tumor microenvironment [2,5,10]. The
development of FDA approved therapies for combating ccRCC
has been heavily influenced by an understanding of the molecular
underpinnings of VHL disease. Specifically, small-molecule
tyrosine kinase inhibitors (e.g. sunitinib and pazopanib) have been
developed to inhibit vascular endothelial growth factor receptor
(VEGFR) and platelet derived growth factor receptor (PDGFR)
[3,10]. Additionally, temsirolimus and everolimus, derivatives of
rapamycin, are approved to treat advanced RCC [5]. While
significant tumor responses are seen in the setting of VEGFR
inhibition they are much less common upon mTOR inhibition
suggesting potential compensatory survival and proliferative
mechanisms that can be co-targeted [11,12].
Rapamycin and its derivatives are allosteric inhibitors of the
serine/threonine kinase, mechanistic target of rapamycin
(mTOR), that require rapamycin’s association with cytosolic
protein, FKBP12 [5,13]. mTOR integrates extracellular growth
signals with cellular responses such as proliferation, autophagy,
metabolism, cell growth and survival [14]. The mTOR protein
kinase interacts with several proteins to form two distinct
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complexes, mTORC1 and mTORC2. Both mTORC1 and
mTORC2 are composed of the common subunits: DEP domain
containing mTOR-interacting protein (DEPTOR), mammalian
lethal with sec-13 protein 8 (mLST8), and tti1/tel2 complex.
However, they differ in composition by several additional proteins.
Regulatory-associated protein of mammalian target of rapamycin
(Raptor) and proline-rich AKT substrate 40 KDa (PRAS40) are
distinct to the mTORC1 signaling complex while rapamycin-
insensitive companion of mTOR (Rictor), mammalian stress-
activated map kinase-interacting protein1 (mSin1), and protein
observed with Rictor 1 and 2 (protor1/2) are associated with
mTORC2 [15]. Notably, the mTORC2 complex is thought to be
relatively insensitive to rapamycin [16]. Furthermore, treatment
with rapamycin and it’s derivatives causes a release of negative
feedback on the PI3K/AKT signaling pathway [17,18]. There-
fore, the inability of rapamycin to inhibit all signaling nodes of
mTOR has warranted efforts to develop catalytic mTOR
inhibitors capable of perturbing mTOR’s kinase activity and
therefore blocking both mTORC1 and mTORC2 complexes
[19].
However, recent reports have demonstrated that inhibitors of
mTOR are capable of increasing MEK/ERK activation and its
associated proliferation and survival signaling in cancer cells [20–
26]. Interestingly, several groups have observed that catalytic
mTOR inhibition increases compensatory MEK/ERK signaling
greater than allosteric mTOR inhibition [23,27]. This particular
observation has resulted in pre-clinical and clinical studies utilizing
mTOR inhibition in combination with MEK inhibition for
treating several cancer types [26,28–30]
Here, we investigate, through both a pharmacologic and genetic
approach, the compensatory proliferation and survival pathways
observed in the context of allosteric and catalytic mTOR
inhibition. The studies conducted here support that catalytic
mTOR inhibition may be better than allosteric inhibition at
restraining cellular proliferation and increasing apoptosis. How-
ever, we also observe that catalytic mTOR inhibition is more
robust at initiating compensatory MEK/ERK signaling in RCC.
We address these compensatory cross-talk pathways through
pharmacologic inhibition and demonstrate that the selected
combinatorial approaches reveal an enhanced effect at attenuating
cellular proliferation and augmenting the apoptotic response in
RCC cells.
Results
Novel renal cell carcinoma cell lines lack VHL and
overexpress HIF
In order to aid our studies, we generated two novel ccRCC cell
lines (hereafter called UNC-R1 and UNC-R2) from primary
patient-derived xenografts (PDX). H&E staining of a portion of the
PDX tumor demonstrated clear cell histology (Figure 1A). Cell
morphology of the cell lines remained consistent over time. To
characterize these novel cell lines, VHL, HIF1a, and HIF2a
expression were determined by western blot (Figure 1B). RCC4 2-
1 (VHL null) and RCC4 3–14 (VHL wt) were used as controls to
validate current findings. Both the UNC-R1 and the UNC-R2 cell
lines lacked appreciable expression of VHL. While both cells lines
expressed HIF2a, only UNC-R1 expressed HIF1a (Figure 1B),
suggesting that UNC-R2 cells have lost HIF1a expression as is
seen in a proportion of ccRCC cell lines and primary tumors and
consistent with the notion that HIF1a is potentially a tumor
suppressor gene [31].
Catalytic mTOR inhibitors block mTORC1 signaling more
fully than allosteric mTOR inhibition
Previous studies have demonstrated that the dual catalytic
PI3K/mTOR inhibitor, BEZ235, inhibits mTORC1 signaling
better than allosteric mTOR inhibition with rapamycin or other
rapalogs [32–36]. We wished to see whether these results could be
replicated in our hands. Dose titrations of rapamycin and BEZ235
in a panel of human RCC cell lines showed that 200 nM and
1 uM respectively were required to inhibit mTORC1 and/or
mTORC2 signaling (Figure S1A and S1B). These doses of
rapamycin and BEZ235 were therefore used to treat a panel of
RCC cell lines. As expected, while both compounds inhibited the
phosphorylation of S6, only BEZ235 inhibited phosphorylation of
4EBP1 and AKT Ser 473 (Figure 2). Moreover, as previously
described, allosteric mTOR inhibition with rapamycin resulted in
increased pAKTS473 expression in 786-0, RCC4, and UNC-R2
cells (Figure 2) presumably as a result of release of S6K and IRS1
dependent negative feedback inhibition of PI3K/AKT signaling
[17].
Catalytic mTOR inhibition is superior to allosteric mTOR
inhibition at attenuating cellular proliferation and
inducing apoptosis
Previous groups have demonstrated that BEZ235 is better than
rapamycin at decreasing cellular proliferation in RCC [33]. We
utilized CellTiter-Glo to measure alterations in cellular viability
over the course of 4 days. Consistent with previous results, our
data show that BEZ235 inhibits cellular proliferation better than
rapamycin (Figure 3A and Figure S2). Interestingly, both primary
cell lines (UNC-R1 and UNC-R2), but especially UNC-R2,
seemed exquisitely sensitive to BEZ235 as evidenced by signifi-
cantly fewer cells present at day 4 than to day 0 (Figure 3A).
While they prolong overall survival, allosteric mTOR inhibitors
such as everolimus and temsirolimus have displayed little cytotoxic
effects in patients (i.e. they lead to few objective responses) [12].
Catalytic mTOR inhibitors have shown increased efficacy in
generating an apoptotic response in preclinical studies, likely as a
result of decreasing AKT mediated survival signals [32,34].
Treatment of RCC4, 786-0, and RCC10 cells with BEZ235
resulted in increased apoptosis as evidenced by the increased
expression of the apoptotic marker, cleaved PARP (poly ADP
ribose polymerase) (Figure 3B). Moreover, BEZ235 also increased
expression of another apoptotic marker, cleaved-caspase 3, in
RCC4 and RCC10 cells (Figure S3). Interestingly, 786-0 and
RCC4 cells showed a decrease in cleaved-PARP expression when
treated with rapamycin (Figure 3B) likely as a consequence of the
increased survival signaling from AKT (Figure 2). Additionally,
assessment of apoptosis by flow cytometry (Annexin V+/PI-
fraction) also showed that RCC cells treated with BEZ235 had
increased apoptosis respective to rapamycin treated cells (Fig-
ure 3C). Therefore, catalytic mTOR inhibition is superior to
allosteric mTOR inhibition at attenuating cellular proliferation
and inducing apoptosis.
mTORC2 activity negatively regulates the apoptotic
response through phosphorylation of AKT
We wanted to determine whether the enhanced apoptosis seen
with BEZ235 treatment (relative to rapamycin) was due to its
ability to inhibit mTORC2 and subsequent downregulation of
AKT dependent survival signaling. Since there are no pharma-
cologic inhibitors capable of specifically inhibiting mTORC2, we
silenced Rictor expression, which is required for mTORC2
activity (Figure 3D). Knock-down of Rictor significantly decreased
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Figure 1. Novel renal cell carcinoma cell lines lack VHL and overexpress HIF. (A) Photomicrographs of H&E stains (left panels) and bright
field images (right panels) of UNC-R1 and UNC-R2 PDX derived cell lines. (B) Whole cell extracts from UNC-R1 and UNC-R2s were immunoblotted with
the indicated antibodies. RCC4 2-1 (VHL null) and RCC4 3–14 (VHL positive) were included as controls.
doi:10.1371/journal.pone.0104413.g001
Figure 2. Catalytic mTOR inhibitors block mTORC1 signaling more fully than allosteric mTOR inhibition. The indicated cell lines were
treated with the allosteric and catalytic mTOR inhibitors (rapamycin and BEZ235 respectively) at the indicated concentrations for 24 hrs. Whole cell
extracts were then immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0104413.g002
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expression of pAKTS473 and pAKTT308 as well as increased
cleaved-PARP (Figure 3E). In contrast, knock-down of Raptor,
which is required for mTORC1 activity, appeared to slightly
decrease cleaved-PARP expression while mildly increasing
pAKTS473 or pAKTT308 expression. These results support the
notion that the increased apoptosis seen with BEZ235 relative to
rapamycin treatment are a result of BEZ235’s inhibition of
mTORC2 activity.
mTOR inhibition induces compensatory activation of
MEK/ERK signaling
Recent reports have demonstrated cross-talk between the
mTOR and MEK/ERK signaling pathways [37]. To see whether
this interplay was present in the context of RCC we examined the
response of ERK and a canonical ERK substrate, p90RSK, to
rapamycin or BEZ235. Both pERK and p-p90RSK were induced
by allosteric and catalytic mTOR inhibition (Figure 4A). While
there was a sense that BEZ235 treatment resulted in a slightly
larger increase in p-p90RSK in a subset of the cell lines, this was
not accompanied by the same amount of induction of pERK. This
could reflect enhanced ERK activity that is not appreciable by
pERK western blotting or mTOR inhibition induced p-p90RSK
that is ERK independent. However, ERK is the only described
kinase to phosphorylate p90RSK on the S380 site [38]. Overall,
these results suggest that mTOR inhibition of RCC cells
upregulates MEK/ERK signaling and that catalytic mTOR
inhibition may do so in a more robust manner than allosteric
inhibition.
Combination of mTOR and MEK inhibition attenuates
cellular proliferation and increases the apoptotic
response
The observation of increased MEK/ERK signaling in the
context of mTOR inhibition led us to hypothesize that attenuation
of this compensatory signal may decrease cellular proliferation and
induce apoptosis. We saw that 10 nM of the MEK inhibitor
GSK1120212 (hereafter called GSK212) was sufficient to fully
inhibit MEK activity as assessed by pERK T202/Y204 in several
RCC cell lines (Figure 4B). Treatment of RCC cell lines with
rapamycin or BEZ235 led to a decrease in the percentage of cells
in S phase as determined by Edu incorporation (Figure 4C). The
combination of MEK inhibition with mTOR inhibition led to a
potent reduction in S phase fraction, particularly when GSK212
was combined with BEZ235. As expected, MEK inhibition led to
hypophosphorylation of Rb as well as downregulation of cyclin B1
and cyclin D1 consistent with increased cell cycle arrest. However,
the addition of mTOR inhibition did not further change levels of
these proteins (Figure 4D).
Despite the fact that the combination of BEZ235 and GSK212
potently inhibited cell cycle progression, there did not appear to be
an additive effect on proliferation or colony formation (Figure 4E
and 4F). We hypothesized that this lack of additivity was secondary
to the high level of inhibition of proliferation and colony formation
by 1 mM BEZ235 alone. Therefore, we determined the IC50 for
BEZ235 in several RCC cell lines (Figure S4A), confirmed that the
determined IC50 was capable of inducing activation of MEK/
ERK signaling (Figure S4B), and examined its effects on
proliferation on colony formation. The combination of 2 nM of
BEZ235 with GSK212 resulted in significant decreases in
proliferation (Figure S5A) and colony formation (Figure S5B)
over either single agent alone. Furthermore, the combination of
mTOR inhibition with MEK inhibition augmented the apoptotic
response as evidence of increased C-PARP expression in 786-0
and RCC4 cells treated with the combination (Figure 4G).
Together, these data support the notion that combined mTOR
and MEK inhibition might be an effective therapy in RCC.
Subclasses of RCC can be defined by MEK and mTOR
pathway activation
To assess the potential relevance of MEK and/or mTOR
inhibition in ccRCC we examined reverse phase protein array
data (RPPA) from the TCGA clear cell kidney cancer project
(KIRC) to determine the relative activation state of these pathways
in human RCC [39]. Reverse phase protein arrays are a highly
validated technique allowing the assessment of protein expression
across hundreds of proteins simultaneously and because of the
multiplatform nature of the TCGA allows for correlations to other
genomic aspects of a tumor. To this end, TCGA KIRC tumors
were hierarchically clustered using log2 transformed, median
centered, RPPA expression data of canonical phosphoproteins that
represent activation of the MEK (pERKT202/Y204), PI3K
(pAktT308), mTORC1 (p4E-BP1T70, p4E-BP1T37, pS6S235/236,
pS6S240/244, p70S6KT389) and mTORC2 (pAktS473) pathways
(Figure 5A). There were 4 well-defined clusters of tumors that
appeared to represent differential patterns of MEK and mTOR
activation: 1) MEK activation [I: black]. 2) dual MEK and mTOR
activation [II: red]. 3) no activation [III: green]. and 4) mTOR
activation [IV: blue]. These subgroups could be also visualized
using a plot that graphed the relative expression of the canonical
markers of MEK activation (pERKT202/Y204) and mTORC1
activation (pS6S235) (Figure 5B).
Finally, we wanted to see if our MEK/mTOR subgroups held
prognostic value and thus assessed their patterns of overall
survival. We found that patients with mTOR activated tumors
(IV: blue) had the worse overall survival while patients with high
MEK activation, regardless of mTOR status, had the best survival
(I: black and II: red) (Figure 5C). Patients with RCC tumors
without activation (III: green) had an intermediate overall survival.
Therefore, subclasses of RCC tumors can be identified based on
their relative activation of the MEK and mTOR pathways and the
subclasses correlate with prognosis.
Discussion
Our studies investigate the relative efficacy of allosteric versus
catalytic mTOR inhibition in RCC through both pharmacologic
and genetic approaches. We show that as monotherapy, catalytic
mTOR inhibition is better at decreasing cellular proliferation and
inducing apoptosis than allosteric mTOR inhibition consistent
with previous studies in RCC [33]. However, despite these
potentially therapeutically beneficial characteristics, we show that
Figure 3. Catalytic mTOR inhibition attenuates proliferation and induces apoptosis better than allosteric mTOR inhibition. (A) The
indicated cell lines were assessed for viability on the indicated days using CellTiter-Glo. Statistical significance was determined by comparing
rapamycin and BEZ235 treated groups. (B) The indicated cell lines were treated with rapamycin and BEZ235 for 48 hours and immunoblotted with
the indicated antibodies. (C) The indicated cell lines were treated with rapamycin and BEZ235 for 48 hours and assessed for apoptosis by flow
cytometry analysis of the Annexin V+/PI – fraction. (D) 786-0 cells were stably infected with shRNAs targeting Raptor (mTORC1) or Rictor (mTORC2)
and confirmed for knock-down by western blot. (E) Whole cell extracts from 786-0 shNS, shRaptor, and shRictor cells were immunoblotted with the
indicated antibodies.
doi:10.1371/journal.pone.0104413.g003
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catalytic mTOR inhibition also induces a more robust induction of
compensatory MEK/ERK signaling. Nonetheless, the compensa-
tory upregulation in MEK/ERK signaling can be targeted with
small molecule kinase inhibition, resulting in enhanced therapeutic
efficacy. Finally, we demonstrate that primary RCC tumors can be
classified based on their relative activation of the MEK and
mTOR pathways and that these different MEK/mTOR subtypes
are associated with differences in overall survival.
Dual inhibition of the MEK and PI3K/mTOR pathways has
shown preclinical promise as a therapeutic strategy in a variety of
tumors [24–26,28,40–42] and has entered into phase 1 trials in
humans [29]. Inhibition of the MEK/ERK and PI3K/mTOR
pathways is a rational strategy based on the extensive crosstalk
between the two pathways and the well documented compensa-
tory signaling that occurs in the face of MEK or mTOR inhibition
[37]. Nonetheless, neither dual inhibition nor the compensatory
cross-talk between the MEK and PI3K/mTOR pathways has
been explored specifically in the context of RCC where it is highly
clinically relevant given the approval of the allosteric mTOR
inhibitors everolimus and temsirolimus for patients with advanced
disease [12]. Therefore, our studies are the first to investigate this
crosstalk and its potential clinical relevance in RCC.
Our studies showed that mTOR inhibition in RCC cell lines
resulted in increased MAPK signaling in the context of both
allosteric and catalytic mTOR inhibition (Figure 4A). Moreover,
we noted that catalytic mTOR inhibition enhanced ERK
phosphorylation, as well as phosphorylation of the ERK substrate,
p90RSK more than robustly than allosteric mTOR inhibition
(Figure 4A and G). Precisely how mTOR inhibition in RCC
results in increased MEK/ERK signaling remains to be
determined. Further investigation into this is warranted but
overall our results are consistent with the notion that kinase
inhibition results in upregulation of compensatory pathways and
kinome reprogramming [43].
Examination of the RPPA data from the TCGA KIRC project
allowed us to assess the possibility that RCC could be divided into
subclasses based on the relative activation of the MEK and
mTOR pathways as well as evaluate their potential therapeutic
significance [39]. We have named these groups, MEK activated,
mTOR activated, dual MEK and mTOR activated, and not
activated. We propose that rational targeted therapy for the
MEK/mTOR subgroups might include: MEK activated – MEK
inhibitor, mTOR activated – allosteric or catalytic mTOR
inhibitor, dual MEK and mTOR activated – combination MEK
and mTOR inhibitor, and not activated – VEGFR tyrosine kinase
inhibitor.
Patients with mTOR activated tumors had the worse overall
survival relative to the other subgroups and are also the only
subgroup that would be predicted to benefit from single agent,
allosteric mTOR inhibition. Intriguingly, temsirolimus has been
shown in a phase III randomized trial to prolong the overall
survival of patients with ‘‘poor prognosis’’ as defined by the
MSKCC criteria [12,44]. While we cannot be sure that our
mTOR activated group corresponds to the ‘‘poor prognosis’’
patients defined by the MSKCC criteria, if they do correlate, our
data provides a biological explanation for this interesting clinical
observation.
In summary, our studies demonstrate that catalytic mTOR
inhibition is more effective than allosteric, but that catalytic
mTOR inhibition appears to more robustly induce alternative
compensatory pathways (i.e. MEK/ERK). Nonetheless, compen-
satory upregulation of MEK/ERK signaling can be co-targeted
with enhanced therapeutic effectiveness. Furthermore, we describe
distinct subclasses of RCC that can be defined by the activation of
the MEK and mTOR pathways, have clinically distinct prognosis,
and would be predicted to have differential responses to MEK and
mTOR kinase inhibition. In aggregate, our data suggests that
catalytic mTOR inhibition should be investigated in RCC and
that the compensatory upregulation of MEK/ERK signaling may
actually be a potential synthetic vulnerability in RCC.
Materials and Methods
Patient-derived xenograft cell isolation
Xenografts were excised and washed in a solution of Pen-Strep,
1XPBS solution (1:1). In sterile conditions, xenografts were then
cut into small 262 mm fragments and dissociated in gentleMACS
C-Tube (Miltenyi Biotec) using the gentleMACs Dissociator
(program: m_imp Tumor_02) in 5 mL of complete DMEM.
Then 100 mL of collagenase D/dispase II (Roche: 40 mg/mL) was
added to the tumor fragments and continuously inverted for
30 min at 37uC. Fragments were then subjected to another round
of dissociation using the gentleMACS Dissociator (program:
m_imp Tumor_03). 5 mL of protein extraction buffer (PEB:
buffer 0.5% FBS, 2 mM EDTA in PBS) was added to the
dissociated fragments and resuspended by pipetting. The cell
suspension was transferred to a 50 mL conical tube through a
40 mm nylon mesh sterile cell strainer (Fisher). An additional
20 mL of PEB buffer was added to the cell suspension and it was
then centrifuged at 300 g’s for 5 min. Supernatant was removed
and cell pellet was resuspended in 6 mL of complete DMEM and
placed in a 6 cm sterile cell culture plate. De-identified tumor
tissue was obtained from the University of North Carolina
Institutional Review Board (IRB) approved tissue procurement
facility after University of North Carolina IRB approval. The
animal work was approved by the University of North Carolina
Institutional Animal Care and Use Committee.
Cell lines and culture conditions
RCC10, 786-0, RCC4, UNC-R1, UNC-R2 were cultured in
complete DMEM (CORNING-Cellgro #10-013-CV) supple-
mented with 10%FBS, 16 Penn/Strep at 37uC, 5% CO2, 21%
O2. 786-0 cells were obtained from ATCC. RCC4 cells were
obtained from Dr. Kimryn Rathmell [45] and RCC10 cells were
obtained from Dr. Michael Ohh [46]. RCC tumor tissue from de-
identified patients were obtained from the University of North
Carolina Institutional Review Board (IRB) approved tissue
procurement facility after IRB approval. UNC-R1 and UNC-R2
Figure 4. Combined mTOR and MEK inhibition attenuates cellular proliferation and increases the apoptotic response. (A) The
indicated cells were treated for 24 hrs. with rapamycin or BEZ235 and immunoblotted with the indicated antibodies. (B) 786-0 and RCC4 cells were
treated increasing doses of GSK212 for 24 hrs. and immunoblotted with the indicated antibodies. (C) 786-0 and RCC4 cells were treated for 24 hrs
with rapamycin and BEZ235 in the presence of Edu. Edu incorporation was assessed by flow cytometry. (D) 786-0 and RCC4 cells were treated with
the indicated compounds for 24 hrs. Whole cell extracts were immunoblotted for the cell cycle related proteins indicated. (E) 786-0 and RCC4 cells
were treated with indicated drugs and assessed for viability on day 4 using CellTiter-Glo 4. (F) 786-0 and RCC4 cells were plated, allowed to attach,
and treated with the indicated drug(s). Photographs of wells containing 786-0 (day 11) and RCC4 (day 17) cells fixed with 4% PFA and stained with
0.1% crystal violet. (G) 786-0 and RCC4 cells were treated with the indicated compounds for 24 hrs. Whole cell extracts were immunoblotted with the
indicated antibodies.
doi:10.1371/journal.pone.0104413.g004
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Figure 5. Subclasses of RCC can be defined by MEK and mTOR pathway activation. (A) TCGA KIRC RPPA data was log2 transformed,
median centered. Tumors were then hierarchically clustered and the indicated subgroups were determined based on expression patterns of the
indicated phosphoproteins. Mutational data for mTOR pathway related genes were annotated in the upper tracks. (B) Scatter plot of TCGA KIRC
tumors based on expression of pS6 and pERK. Each dot indicates a tumor. The MEK-PI3K/mTOR subclasses defined in (A) are indicated by color. (C)
Patients harboring tumors within each MEK-PI3K/mTOR subclass were evaluated for differences in overall survival by the Log Rank test and shown as
a Kaplan-Meier plot of overall survival.
doi:10.1371/journal.pone.0104413.g005
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cell lines were generated as above from the renal patient derived
xenografts. BEZ235 (Center for Integrative Chemical Biology &
Drug Discovery, UNC Eshelman School of Pharmacy),
GSK1120212 (GlaxoSmithKline), Rapamycin (LC Laboratories)
were dissolved in DMSO.
Immunoblot conditions
Cells were lysed in RIPA buffer complemented with Set I and
Set II phosphatase inhibitors at 16 (Calbiochem), and protease
inhibitors at 16 (Roche). Whole cell lysate concentration was
determined with Bio-Rad Protein Assay Dye Reagent Concentrate
(Bio-Rad). Proteins were resolved on SDS-PAGE gels and
electrotransferred to nitrocellulose membranes, 0.2 mm (Bio-
Rad). Primary antibodies pS6S235/236, S6, pAKTS473, AKT,
p4E-BP1T37/46, 4E-BP1, Cleaved PARP, pAktT308, p62, Rictor,
Raptor, HIF-1a, HIF-2a, pERK1/2T202/Y204 (mouse), ERK, p-
p90RSKS380, RSK1/2/3, pBADS112, pBADS136, pEGFRY1068,
cleaved-caspase3 were from Cell Signaling Technologies. VHL
(Santa Cruz #FL-181). mTOR primary antibody was from
Millipore. Primary antibody dilutions were to manufactures’
specifications (See Table S1). Tubulin (Sigma #T5168), KU-80
(GeneTex #GTX70485) and Actin-HRP (Santa Cruz #C-11)
primary antibodies served as loading controls (LC) where noted.
Secondary anti-Rabbit and ant-mouse antibodies were from
(Fisher) and diluted in 5% milk, 16 TBS-T solution. ECL
Western Blotting Detection reagents (GE Healthcare) were used
for developing blots onto autoradiography film. For difficult to
detect proteins SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Scientific) was used in combination with ECL.
Cell viability assay
To determine cell viability in the context of the various culture
conditions we used a CellTiter-Glo Luminescent Cell Viability
Assay (Promega) per manufacture’s protocol. Cells were counted
and plated in quadruplicate in a 96 well opaque side/clear bottom
cell culture plates (Corning) in culture medium containing the
noted concentration. Luminescence measurements were captured
using a Biotek Synergy 2 plate reader. 2-way ANOVA analysis was
used to determine statistical significance.
Cell cycle analysis by flow cytometry
Cells were plated in triplicate and treated for 24 hrs with
indicated drug. Cell cycle analysis was performed by EdU
incorporation using Click-iT EdU Alexa Fluor 647 flow assay kit
(Invitrogen, catalog number C-10424) according to the manufac-
turer’s instructions. After treatment cells were exposed to 10 mM
EdU for 2 h. Cells were then dissociated with 0.05% Trypsin/
EDTA and fixed immediately, with 4% PFA, for incorporated
EdU detection. Total DNA content was stained with propidium
iodide (PI) at 10 mg/ml after RNase A treatment. Flow cytometry
was performed on a CyAnTM ADP flow cytometer (Dako,
Glostrup, Denmark) and data analysis was performed using
FlowJo software (Tree Star, Inc.). Statistical significance was
measured by Student’s T-Test.
Apoptosis analysis by flow cytometry
Cells were plated in duplicate and treated with the indicated
drug for 48 hrs. Percentage of apoptotic cells were determined by
staining with Annexin V Alexa Fluor 488 & PI (Dead Cell
Apoptosis Kit, Invitrogen, cat# V13241) according to the
manufacturer’s instructions. Flow was performed on a Dako
CyAn ADP and data were analyzed using FlowJo software.
Statistical significance was measured by Student’s T-Test.
RNAi experiments
pLKO.1 shRNA plasmids were obtained form the UNC Viral
Vector Core, packaged and infected per manufacture’s protocols.
Addgene catalogue numbers: shNS (#1864), shRictor (#1853),
shRaptor (#1857), shmTOR (#1853). Cells were incubated with
viral media over-night, and replaced with fresh complete media.
Selection with 1 mg/mL puromycin was started 48 hrs later.
Colony formation assay
RCC cells were plated at low-density in a 6 well plate (786-0: 50
cell/well and RCC4: 100 cells/well). Cells were allowed to attach
and treated with indicated drug(s). Treatment conditions were
changed every 72 hrs. Cells were fixed with 4% PFA and stained
with crystal violet.
TCGA data analysis
TCGA KIRC RPPA protein data was log2 transformed and
median centered. Tumors samples (n = 454) and proteins relating
to ERK and mTOR signaling were hierarchically clustered by
centroid linkage using Cluster 3.0 and protein clusters were
determined based on tumors sharing a common node. Mutations
in mTOR related genes were annotated and superimposed as
tracks above the heatmap for visualization. Scatter and Kaplan-
Meier plots were generated in R (http://cran.r-project.org).
Survival differences were determined by log-rank test.
Supporting Information
Figure S1 Dose titrations of rapamycin and BEZ235.
The indicated cell lines were treated with increasing doses of
rapamycin (A) or BEZ235 (B) for 24 hours. Whole cell extracts
were immunoblotted with the indicated antibodies to evaluate
changes in mTORC1 and mTORC2 signaling.
(TIF)
Figure S2 Proliferation curve of RCC10 cells. RCC10
cells were treated over the course of 4 days with the indicated
drugs and assessed for viability using CellTiter-Glo.
(TIF)
Figure S3 Apoptosis in response to rapamycin or
BEZ235 treatment. RCC10 and RCC4 cells treated with
rapamycin or BEZ235 for 24 hrs and analyzed by western blot for
apoptotic marker cleaved-caspase 3.
(TIF)
Figure S4 Dose titrations of BEZ235. (A) 786-0 and RCC4
cells were plated and treated with a dose titration of BEZ235 and
IC50 value determined using CellTiter-Glo cell viability reagent.
(B) 786-0 and RCC4 cells were treated with 2 nM BEZ235 over a
24 hr. time course and immunobloted for protein expression of
mTORC1, mTORC2, and MEK/ERK signaling proteins.
(TIF)
Figure S5 Combinatorial effects of mTOR and MEK
inhibition. (A) 786-0 and RCC4 cells were treated with indicated
drugs and assessed for viability on day 4 using CellTiter-Glo. Statistical
significance was determined by comparing rapamycin and BEZ235
treated groups (B) 786-0 and RCC4 cells were plated, allowed to
attach, and treated with 200 nM rapamycin, 2 nM BEZ235, 10 nM
GSK212. Photographs of wells containing 786-0 and RCC4 cells fixed
with 4% PFA and stained with 0.1% crystal violet.
(TIF)
Table S1 List of antibodies used including company and
catalogue number.
(DOCX)
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